相关实验视频
Updated: Jun 9, 2025

Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
设计,合成和生物评估基于4,6-二四素的KDM4D抑制剂
Dongxuan Ni1, Xuechun Chen2, Hairong Wang1
1Key Laboratory of Medicinal Chemistry for Natural Resource of Ministry of Education, School of Chemical Science and Technology, School of Pharmacy, School of Life Sciences, Yunnan Characteristic Plant Extraction Laboratory, Yunnan Research & Development Center for Natural Products, State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Yunnan University, Kunming, China.
研究人员开发了针对癌症治疗的新型4,6-二基诺素化合物,这些化合物准了Histone lysine脱甲酶4D (KDM4D). 化合物33a证明了肝癌细胞活力,增殖和迁移的强有力的抑制,显示出作为抗瘤药物领先的承诺.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 基因组 lysine 脱甲基酶 4D (KDM4D) 与瘤发生有关.
- KDM4D是抗癌药物开发的潜在治疗标.
研究的目的:
- 设计和合成新的KDM4D抑制剂.
- 评估这些抑制剂的抗癌潜力,特别是对抗肝癌.
主要方法:
- 基于已知的支架,合成4,6-二基诺素衍生物.
- 在体外测试以确定对KDM4D和肝癌细胞 (Huh-7) 的抑制功效 (IC50).
- 对细胞循环进展,增殖和迁移的影响的评估.
主要成果:
- 化合物33a成为最强大的KDM4D抑制剂 (IC50 = 0.62μM).
- 33a有效抑制了Huh-7肝癌细胞的活力 (IC50 = 5.23μM).
- 33a显著抑制了癌细胞的增殖和迁移.
结论:
- 4,6-二基诺素支架对开发KDM4D抑制剂具有前景.
- 化合物33a代表了针对KDM4D的新型抗瘤药物开发的潜在主要化合物.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11:17Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
Published on: June 13, 2019
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Inhibition of Cdk Activity
Drug Discovery: Overview